Workflow
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
NRSNNeuroSense Therapeutics(NRSN) Prnewswire·2024-12-02 13:30

Core Viewpoint - NeuroSense Therapeutics Ltd. has entered into a definitive agreement for a private placement to raise 5,000,000throughthesaleofordinarysharesandwarrants,aimedatsupportingitsdevelopmentoftreatmentsforsevereneurodegenerativediseases[1][2].Group1:PrivatePlacementDetails−Thecompanywillsellatotalof4,000,000ordinarysharesand8,000,000warrants,withacombinedpurchasepriceof5,000,000 through the sale of ordinary shares and warrants, aimed at supporting its development of treatments for severe neurodegenerative diseases [1][2]. Group 1: Private Placement Details - The company will sell a total of 4,000,000 ordinary shares and 8,000,000 warrants, with a combined purchase price of 1.25 per share, which is 25% above the closing price on November 29, 2024 [2]. - The warrants will have a term of five years and an exercise price of $1.25 per share [2]. - The proceeds from the private placement will be delivered in two tranches and are expected to be used for general corporate and working capital purposes [3]. Group 2: Company Overview - NeuroSense Therapeutics is focused on developing treatments for debilitating neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease, which represent significant unmet medical needs [6]. - The company aims to develop combined therapies targeting multiple pathways associated with these diseases, based on strong scientific research and a large panel of related biomarkers [6].